U.S. Postpartum Depression Rate Doubles to 19% by 2021 as Zurzuvae Becomes First Pill

3 articles · Updated · The Mercury · Jun 7

U.S. postpartum depression affected 19% of new mothers in 2021, up from 9.4% in 2010, according to a 2024 JAMA Network Open study cited in the report.
Improved screening and diagnosis helped drive the increase, with doctors often using a 10-question postpartum checkup tool to flag persistent sadness, panic, worry and other symptoms needing evaluation.
More severe warning signs include despair lasting beyond two weeks, anxiety, guilt, loss of interest, poor sleep and thoughts of self-harm; untreated cases can disrupt bonding and raise suicide risk.
Zurzuvae is the first pill approved specifically for postpartum depression, alongside antidepressants, talk therapy, sleep and family support as treatment options.
Doctors and patient advocates say early help from OB-GYNs, primary care or mental health providers can lead to recovery and prevent mothers from suffering in silence.

Sources

As PPD rates soar, does 'better screening' mask a deeper crisis in how society supports new mothers?

With a new 14-day pill for PPD, are we at risk of medicating the symptoms while ignoring the cause?

Since nearly 10% of new fathers also suffer postpartum, why is the crisis framed almost exclusively around mothers?